{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T20:00:21Z","timestamp":1759694421853},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T00:00:00Z","timestamp":1114128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00262-005-0686-1","type":"journal-article","created":{"date-parts":[[2005,4,21]],"date-time":"2005-04-21T08:39:32Z","timestamp":1114072772000},"page":"1172-1179","source":"Crossref","is-referenced-by-count":16,"title":["A DeImmunized chimeric anti-C3b\/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation"],"prefix":"10.1007","volume":"54","author":[{"given":"Wu","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehal","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pecora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda L.","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve E.","family":"Pincus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie S.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Spitalny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,4,22]]},"reference":[{"key":"686_CR1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","volume":"14","author":"J Boye","year":"2003","unstructured":"Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520","journal-title":"Ann Oncol"},{"key":"686_CR2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754","journal-title":"Blood"},{"key":"686_CR3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443","journal-title":"Nat Med"},{"key":"686_CR4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","volume":"101","author":"MS Cragg","year":"2003","unstructured":"Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR, Glennie MJ (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045","journal-title":"Blood"},{"key":"686_CR5","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","volume":"103","author":"MS Cragg","year":"2004","unstructured":"Cragg MS, Glennie MJ (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738","journal-title":"Blood"},{"key":"686_CR6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","volume":"171","author":"N Di Gaetano","year":"2003","unstructured":"Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581","journal-title":"J Immunol"},{"key":"686_CR7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","volume":"40","author":"Z Fishelson","year":"2003","unstructured":"Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109","journal-title":"Mol Immunol"},{"key":"686_CR8","first-page":"679","volume-title":"Fundamental Immunology","author":"M Frank","year":"1989","unstructured":"Frank M, Fries L (1989) Complement. In: Paul W (ed) Fundamental Immunology. 2nd edn, Raven Press, New York, p 679","edition":"2nd edn"},{"key":"686_CR9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/1521-4141(200201)32:1<128::AID-IMMU128>3.0.CO;2-P","volume":"32","author":"KA Gelderman","year":"2002","unstructured":"Gelderman KA, Kuppen PJ, Bruin W, Fleuren GJ, Gorter A (2002) Enhancement of the complement activating capacity of 17\u20131A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol 32:128","journal-title":"Eur J Immunol"},{"key":"686_CR10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.it.2004.01.008","volume":"25","author":"KA Gelderman","year":"2004","unstructured":"Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25:158","journal-title":"Trends Immunol"},{"key":"686_CR11","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900","journal-title":"Blood"},{"key":"686_CR12","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383","journal-title":"Blood"},{"key":"686_CR13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","volume":"80","author":"ML Grossbard","year":"1992","unstructured":"Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863","journal-title":"Blood"},{"key":"686_CR14","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin\u2019s lymphoma. J Clin Oncol 20:4261","journal-title":"J Clin Oncol"},{"key":"686_CR15","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","volume":"21","author":"JD Hainsworth","year":"2003","unstructured":"Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746","journal-title":"J Clin Oncol"},{"key":"686_CR16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","volume":"51","author":"A Harjunpaa","year":"2000","unstructured":"Harjunpaa A, Junnikkala S, Meri S (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51:634","journal-title":"Scand J Immunol"},{"key":"686_CR17","first-page":"5866","volume":"9","author":"FJ Hernandez-Ilizaliturri","year":"2003","unstructured":"Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin\u2019s lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 9:5866","journal-title":"Clin Cancer Res"},{"key":"686_CR18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","volume":"98","author":"D Huhn","year":"2001","unstructured":"Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326","journal-title":"Blood"},{"key":"686_CR19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/(SICI)1096-9098(199703)64:3<222::AID-JSO9>3.0.CO;2-C","volume":"64","author":"H Juhl","year":"1997","unstructured":"Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruns D, Kremer B (1997) Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17\u20131A. J Surg Oncol 64:222","journal-title":"J Surg Oncol"},{"key":"686_CR20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0162-3109(99)00006-5","volume":"42","author":"K Jurianz","year":"1999","unstructured":"Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M (1999) Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 42:209","journal-title":"Immunopharmacology"},{"key":"686_CR21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","volume":"36","author":"K Jurianz","year":"1999","unstructured":"Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36:929","journal-title":"Mol Immunol"},{"key":"686_CR22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2002-03-0876","volume":"101","author":"AD Kennedy","year":"2003","unstructured":"Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP (2003) An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101:1071","journal-title":"Blood"},{"key":"686_CR23","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","volume":"172","author":"AD Kennedy","year":"2004","unstructured":"Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172:3280","journal-title":"J Immunol"},{"key":"686_CR24","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.4049\/jimmunol.170.7.3671","volume":"170","author":"MA Lindorfer","year":"2003","unstructured":"Lindorfer MA, Jinivizian HB, Foley PL, Kennedy AD, Solga MD, Taylor RP (2003) B cell complement receptor 2 transfer reaction. J Immunol 170:3671","journal-title":"J Immunol"},{"key":"686_CR25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","volume":"101","author":"O Manches","year":"2003","unstructured":"Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949","journal-title":"Blood"},{"key":"686_CR26","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825","journal-title":"J Clin Oncol"},{"key":"686_CR27","first-page":"129","volume":"149","author":"GA Niehans","year":"1996","unstructured":"Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149:129","journal-title":"Am J Pathol"},{"key":"686_CR28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-3083.1985.tb01933.x","volume":"22","author":"B Nilsson","year":"1985","unstructured":"Nilsson B, Nilsson UR (1985) An assessment of the extent of antigenic analogy between physiologically bound C3 and C3 denatured by sodium dodecyl sulphate. Scand J Immunol 22:703","journal-title":"Scand J Immunol"},{"issue":"Pt 3","key":"686_CR29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1042\/bj2820715","volume":"282","author":"B Nilsson","year":"1992","unstructured":"Nilsson B, Grossberger D, Nilsson Ekdahl K, Riegert P, Becherer DJ, Nilsson UR, Lambris JD (1992) Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. Biochem J 282(Pt 3):715","journal-title":"Biochem J"},{"key":"686_CR30","doi-asserted-by":"crossref","unstructured":"Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J (2001) Immunotherapy of Non-Hodgkin\u2019s lymphomas. Hematology (Am Soc Hematol Educ Program) :221","DOI":"10.1182\/asheducation-2001.1.221"},{"key":"686_CR31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s002620000140","volume":"49","author":"MH Sokoloff","year":"2000","unstructured":"Sokoloff MH, Nardin A, Solga MD, Lindorfer MA, Sutherland WM, Bankovich AJ, Zhau HE, Chung LW, Taylor RP (2000) Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunol Immunother 49:551","journal-title":"Cancer Immunol Immunother"},{"key":"686_CR32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","volume":"24","author":"SP Treon","year":"2001","unstructured":"Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC (2001) Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother 24:263","journal-title":"J Immunother"},{"key":"686_CR33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev.med.54.101601.152442","volume":"54","author":"M Mehren von","year":"2003","unstructured":"von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343","journal-title":"Annu Rev Med"},{"key":"686_CR34","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","volume":"21","author":"WK Weng","year":"2003","unstructured":"Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-005-0686-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0686-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T01:23:45Z","timestamp":1586222625000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-005-0686-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,22]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1007\/s00262-005-0686-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,22]]}}}